27352. Adulteration of morphine sulphate tablets, morphine sulphate and atro¬ pine sulphate tablets, nitroglycerin tablets, elixir of barbital, arsenous acid tablets, strychnine sulphate tablets, powdered extract of bella- donna leaves, belladonna ointment, santal oil capsules, and powdered extract of stramonium; Misbranding of strychnine sulphate tablets, cor- rosive sublimate tablets, fluidextract of ephedra, and nitroglycerin tablets. V. S. v. Standard Pharmaceutical Corporation. Plea of guilty. Fine, $500 and costs. (F. & D. no. 36090. Sample nos. 4577-B, 14190-B, 14191-B, 14192-B, 35978-B, 35984-B, 41782-B, 41785-B, 41788-B, 45473-B, 45475-B, 45476-B, 45481-B, 45482-B, 45485-B, 45486-B, 61429-B, 61438-B, 61440-B, 61445-B, 64005-B, 70151^-B, 72663-B, 72664-B.) This case involved the following drugs: Powdered extract of belladonna leaves, belladonna ointment, and powdered extract of stramonium, products recognized in the United States Pharmacopoeia, but which differed from the pharmacopoeial standard; one lot each of strychnine sulphate tablets and corrosive sublimate tablets, two lots of nitroglycerin tablets, and one lot of 28022'—37 1 163 fluidextract of ephedra which contained the labeled drugs in excess of the amount declared; and certain lots of strychnine sulphate tablets, nitroglycerin tablets, and various other drugs that contained smaller quantities of the drugs than declared on the labels. On April 16, 1937, the United States attorney for the District of Maryland, acting upon a report by the Secretary of Agriculture, filed in the district court an information against the Standard Pharmaceutical Corporation, Baltimore, Md., alleging shipment by said company in violation of the Food and Drugs Act between the dates of January 9, 1935, and May 13, 19S6, from the State of Maryland into the District of Columbia and the States of Alabama, Georgia, North Carolina, and New York of quantities of the above-named drugs a part of which were adulterated and the remainder of which were misbranded. The articles were labeled variously: "Tablets * * * Morphine Sulphate Y2 Grain [or "% Grain"]"; "Tablets * * * Morphine Sulphate % gr. Atropine Sulphate ^50 gr."; "Tablets Strychnine Sulphate %o Grain [or "1 Grain", "% Grain", or "too"]"; "Tablets Nitroglycerin M.00 Grain [or '%so Grain" or "a too"]"; ''Elixir Barbital * * * Each fluidounce contains Barbital 16 Grains"; "Tablets Arsenous Acid * * * 1 Grain [or "% Grain"]"; "Tablets Corrosive Sublimate 1 Grain"; "Powdered Extract Belladonna Leaves U. S. P. Standard:—1.25% Alkaloids"; "Ointment Belladonna (Unguentum Belladonnae) U. S. P."'; "Powdered Extract Stramonium (Ext. Stramonii) U. S. P. * * * Standard Pharmaceutical Corp. Baltimore, Md."; "Fluid Extract Ephedra * * * Each 10O cc yields 0.5 Gm. of the Alkaloids of Ephedra * * * Prepared For Standard Pharmaceutical Corp."; "Capsules * * * Santal Oil * * * 5 Minims Manufactured For Standard Pharmaceutical Corp." Certain of the products were alleged to be adulterated in that they were sold under names recognized in the United States Pharmacopoeia and differed from the standard of strength, quality, and purity as determined by the test laid down in said pharmacopoeia official at the time of investigation and their standards of strength, quality, and purity were not declared on the containers, viz: The powdered extract belladonna leaves yielded not more than 1.1 percent of the alkaloids of belladonna leaves, whereas the pharmacopoeia provided that extract of belladonna leaves should yield not less than 1.18 percent of the alkaloids of belladonna leaves; the belladonna ointment contained not more than 9 grams of pilular extract of belladonna per 100 grams, whereas the pharmacopoeia provided that belladonna ointment should contain not less than 10 grams of pilular extract of belladonna per 100 grams; the powdered extract stramonium yielded not more than 0.347 percent of the alkaloids of stramonium, whereas the pharmacopoeia provided that extract of stramonium should yield not less than 0.9 percent of the alkaloids of stramonium. Adulteration of the above products and of certain of the others was charged in that their strength and purity fell below the professed standard and quality under which they were sold in the following respects: The powdered extract belladonna leaves, the belladonna ointment, and the powdered extract stramo- nium were represented to conform to the standard laid down in the United States Pharmacopoeia, and the powdered extract belladonna leaves was further labeled as containing 1.25 percent of the alkaloids of belladonna leaves, whereas the products did not conform to said standard and the powdered extract bella- donna leaves contained less than 1.25 percent, namely, not more than 1.1 percent of the alkaloids of belladonna leaves; two of the lots of morphine sulphate tablets were represented to contain one-half grain of morphine sulphate each and one lot was represented to contain one-fourth grain of morphine sulphate per tablet, whereas samples of the former contained 0.37 grain and 0.39 grain of morphine sulphate per tablet and samples from the latter contained not more than 0.18 grain (approximately one-fifth grain) of morphine sulphate; two lots of the strychnine sulphate tablets were represented to contain 1 grain or one-half grain of strychnine sulphate per tablet, whereas the former con- tained not more than 0.78 grain, and the latter not more than 0.414 grain of strychnine sulphate per tablet; certain lots of the nitroglycerin tablets were represented to contain one one-hundredth of a grain of nitroglycerin per tablet, whereas samples from three of the four lots were found to contain 0.005, 0.0056, 0.0055 grain, respectively (approximately one two-hundredth of a grain), of nitrogylcerin and samples from the fourth lot contained 0.0074 (approxi- mately one one-hundred thirty-fifth grain of nitroglycerin; the arsenous acid tablets were represented to contain 1 grain or one-half grain of arsenous acid, whereas the former contained not more than 0.87 (seven-eighths) grain and the latter contained not more than 0.375 (three-eighths) grain of arsenous acid per tablet; the morphine sulphate and atropine sulphate tablets were each represented to contain one-fourth grain of morphine sulphate, whereas they contained not more than 0.215 (approximately one-fifth) grain of morphine sulphate; the elixir barbital was represented to contain 16 grains of barbital per fluid ounce, whereas each fluid ounce contained less than represented, namely, not more than 11.6 grains of barbital; and the santal oil capsules were each represented to contain 5 minims of santal oil, whereas they con- tained less than represented, namely, not more than 4.28 minims of santal oil. The remaining products were alleged to be misbranded in that certain state- ments on the labels were false and misleading in the following respects: One ¦ lot of strychnine tablets were labeled: "Tablets * * * Strychnine Sulphate %o Grain", whereas the tablets contained more than declared, namely, not less than 0.029 approximately (one thirty-fifth) grain of strychnine sulphate; the fluidextract of ephedra was labeled "Fluid Extract Ephedra * * * Stand- ard : Each 10 cc yields 0.5 Gm. of the Alkaloids of Ephedra", whereas each cubic centimeter yielded more than declared, namely, not less than 0.657 gram of ephedra; the corrosive sublimate tablets were labeled "Tablets Corrosive Sublimate 1 Grain'', whereas the tablets contained more than declared, namely, not less than 1.125 grain of corrosive sublimate; two of the lots of nitro- glycerin tablets were labeled, "Tablet * * * Nitroglycerin so [or '%x>"] Grain", whereas the tablets contained more than declared, the former con- taining not less than 0.012 (approximately one-eightieth) grain and the latter containing not less than 0.0083 (one one-hundred and twentieth) grain of nitroglycerin. On May 20, 1937, a plea of guilty was entered on behalf of the defendant and the court imposed a fine of $500 and costs. M. L. WrLsojr, Acting Secretary of Agriculture.